• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[S-腺苷甲硫氨酸(SAMe)口服给药治疗肝硬化及其他慢性肝炎的双盲研究]

[Double-blind studies of the therapeutic action of S-Adenosylmethionine (SAMe) in oral administration, in liver cirrhosis and other chronic hepatitides].

作者信息

Miglio F, Stefanini G F, Corazza G R, D'Ambro A, Gasbarrini G

出版信息

Minerva Med. 1975 May 2;66(33):1595-9.

PMID:1095965
Abstract

Six oral administrations per day of 30 mg S-adenosylmethionine (SAMe) for 30 days, in addition to 6000 gamma/day of Vitamine B12 induced marked improvements of biochemical parameters in 20 patients with hepatic cirrhosis or various chronic hepatites. Particularly, the protidemia, bilirubinemia and radial immunodiffusion have shown the highest favorable drug responses. These improvements were still lasting and even further increasing 30 days after the end of therapy. In another group of patients with similar diagnosis and under clinical conditions comparable to the previous group of twenty, the administration of Vitamine B12 alone, in the same doses as above, has not induced any alteration in the biochemical parameters.

摘要

对于20例肝硬化或各种慢性肝炎患者,每天口服6次,每次30毫克S-腺苷甲硫氨酸(SAMe),持续30天,同时每天补充6000微克维生素B12,结果显示生化指标有显著改善。特别是,蛋白血症、胆红素血症和放射免疫扩散显示出最高的良好药物反应。这些改善在治疗结束后30天仍持续存在,甚至进一步增强。在另一组诊断相似且临床状况与前一组20例相当的患者中,单独给予上述相同剂量的维生素B12,未引起生化指标的任何改变。

相似文献

1
[Double-blind studies of the therapeutic action of S-Adenosylmethionine (SAMe) in oral administration, in liver cirrhosis and other chronic hepatitides].[S-腺苷甲硫氨酸(SAMe)口服给药治疗肝硬化及其他慢性肝炎的双盲研究]
Minerva Med. 1975 May 2;66(33):1595-9.
2
[Double-blind polycentric study of the action of S-adenosylmethionine in hepatic cirrhosis].[S-腺苷甲硫氨酸在肝硬化中作用的双盲多中心研究]
Minerva Med. 1975 May 2;66(33):1590-4.
3
[S-Adenosylmethionine: plasma levels in hepatic cirrhosis and preliminary results of its clinical use in hepatology. Double-blind study].[S-腺苷甲硫氨酸:肝硬化患者的血浆水平及其在肝病临床应用的初步结果。双盲研究]
Minerva Med. 1975 May 2;66(33):1571-80.
4
[Relations between protidopoiesis and biological transmethylations: action of S-adenosylmethionine on protein crasis in chronic hepatopathies].[蛋白质生成与生物转甲基作用之间的关系:S-腺苷甲硫氨酸对慢性肝病中蛋白质组成的作用]
Minerva Med. 1975 May 2;66(33):1581-9.
5
[Therapeutic action of S-adenosylmethionine in some chronic hepatopathies].[S-腺苷甲硫氨酸在某些慢性肝病中的治疗作用]
Minerva Med. 1975 May 2;66(33):1563-70.
6
[The anti-steatosic effect of sulfo-adenosylmethionine (SAMe) in various forms of chronic hepatopathy. Multicentric research].
Minerva Med. 1978 Oct 13;69(48):3283-92.
7
[Controlled clinical trial of 2-mercapto-propionyl-glycine in chronic hepatopathies].2-巯基丙酰甘氨酸治疗慢性肝病的对照临床试验
Minerva Med. 1976 Mar 3;67(11):676-81.
8
[Clinical trial of heptral in patients with chronic diffuse liver disease with intrahepatic cholestasis syndrome].[用贺普丁治疗慢性弥漫性肝病伴肝内胆汁淤积综合征患者的临床试验]
Klin Med (Mosk). 1998;76(10):45-8.
9
[Pharmacological and clinical aspects of S-adenosylmethionine (SAMe) in primary degenerative arthropathy (osteoarthrosis)].[原发性退行性关节病(骨关节炎)中S-腺苷甲硫氨酸(SAMe)的药理及临床研究]
Minerva Med. 1975 Dec 5;66(83):4443-59.
10
[Parenteral S-adenosylmethionine compared to placebos in the treatment of alcoholic liver diseases].[肠外S-腺苷甲硫氨酸与安慰剂治疗酒精性肝病的比较]
An Med Interna. 1996 Jan;13(1):9-15.